Expressão do P16 e do PDGFR-Beta no adenocarcinoma gástrico

Pinto, Rodrigo Silveira; Lima, Fernando Krebs Cirne; Kulkzynski, Jane M U; Moreira, Luís Fernando

doi:10.1590/s0100-69912009000300004

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDGFR-β, Ret, and Kit have potent anti-tumor activity against a number of human tumors through binding with targets ( 44 ). Previous reports have suggested that target receptors of PDGFR-β, Ret, and Kit in gastric tumors are effective treatments ( 45 – 47 ). Although previous contrast media have not previously been compared to determine which media is optimal for the visualization and diagnosis of gastric cancer ( 48 ).…”

Section: Discussionmentioning

confidence: 99%

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Zhang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Gastric cancer is one of the most common human tumors worldwide. The biggest bottleneck is a lack of advanced and sensitive protocols for the diagnosis of patients with early-stage gastric cancer. Therefore, more sensitive methods of diagnosing gastric cancer are urgently required to improve survival rates. In this clinical study, contrast-enhanced computed tomography (CECT) with targeting nanoparticles contrast agent (CECT-TNCA) was used to diagnose early-stage gastric cancer. The specific-targeted tyrosine kinase inhibitors of gastric cancer, including platelet-derived growth factor receptor-β, Ret and Kit, were used as TNCAs. A total of 484 patients with suspected gastric cancer were voluntarily recruited to investigate the efficacy of CECT-TNCA in the diagnosis of patients with early-stage gastric cancer. Patients with suspected gastric cancer were subjected CT and CECT-TNCA to detect whether gastric tumors existed. TNCA was orally administered before CT and CECT-TNCA (20 min). Our diagnostic data revealed that CECT-TNCA improved sensitivity and provided a new protocol to diagnose tumors in patients with suspected gastric cancer at the early stage. In addition, imaging using CECT-TNCA enabled the visualization of tiny nodules in the gastric area. CECT-TNCA diagnosed 182 patients with suspected gastric cancer as tumor-free. CECT-TNCA confirmed gastric cancer in 302 patients. Our novel diagnosis indicated significantly (P<0.01) differential signal enhancement in the gastric nodules via CECT-TNCA compared with CT, suggesting higher accuracy and the accumulation of TNCA in tumor nodules in the stomach. Furthermore, survival rates of patients detected by early-diagnosis of CECT-TNCA were significantly higher than the mean five-year survival (P<0.01). In conclusion, our investigations demonstrate that the sensibility and accuracy of CT is improved through combination with liposome-encapsulated nanoparticle contrast agent for the diagnosis of early stage gastric cancer when compared with single CT detection. CECT-TNCA improves the accuracy of CT and diagnostic confidence in assessing mural enhancement in patients with suspected gastric cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Zhang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

RETRACTED ARTICLE: Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis

2014

View full text Add to dashboard Cite

This meta-analysis was performed to evaluate the relationships between promoter DNA methylation in tumor suppressor gene p16 and gastric carcinogenesis. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library and CBM databases were searched for relevant articles published before November 1st, 2013 without any language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated. Forty-seven clinical cohort studies that met all inclusion criteria were included in this meta-analysis. A total of 2,813 gastric cancer (GC) patients were assessed. Our meta-analysis results revealed that the frequencies of p16 promoter methylation in the GC tissues were higher than those of normal and adjacent tissues (Normal: OR = 23.04, 95% CI = 13.55-39.15, P < 0.001; Adjacent: OR = 4.42, 95% CI = 1.66-11.76, P = 0.003; respectively). Furthermore, we observed significant associations of p16 promoter methylation with TNM stage, histologic grade, invasive grade, lymph node metastasis of GC (TNM stage: OR = 3.60, 95% CI: 2.17-5.98, P < 0.001; Histologic grade: OR = 2.63, 95% CI: 1.55-4.45, P < 0.001; Invasive grade: OR = 3.44, 95% CI: 1.68-7.06, P = 0.001; Lymph node metastasis: OR = 2.68, 95% CI: 1.66-4.32, P < 0.001; respectively). However, there were no correlations of p16 promoter methylation with the TNM stage and Helicobacter pylori (HP) infection of GC (Tumor size: OR = 0.76, 95% CI: 0.14-4.07, P = 0.746; HP infection: OR = 1.31, 95% CI: 0.75-2.27, P = 0.342; respectively). Our findings provide empirical evidence that p16 promoter methylation may play an important role in gastric carcinogenesis. Thus, p16 promoter methylation may be a promising potential biomarker for the early diagnosis of GC.

show abstract

Retraction Note to: Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis

2015

View full text Add to dashboard Cite

show abstract

Expressão do P16 e do PDGFR-Beta no adenocarcinoma gástrico

Cited by 3 publications

References 23 publications

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

Application of novel targeting nanoparticles contrast agent combined with contrast‑enhanced computed tomography during screening for early‑phase gastric carcinoma

RETRACTED ARTICLE: Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis

Retraction Note to: Role of p16 gene promoter methylation in gastric carcinogenesis: a meta-analysis

Contact Info

Product

Resources

About